Shockwave Therapy & High-Power Laser Therapy for Dupuytren’s Contracture

Dupuytren’s contracture is a progressive fibroproliferative disorder that slowly robs people of finger extension and, with it, the ordinary pleasures of a handshake, a flat palm on a table, or a clean grip on a tennis racquet. For decades, the clinical conversation has centred almost exclusively on when to operate. Today, the question is no longer only surgical, it is biological. EMS DolorClast® extracorporeal shockwave therapy (ESWT) and high-power laser therapy (HPLT) target the molecular drivers of Dupuytren’s at their root, offering patients and clinicians a meaningful non-surgical toolkit and a powerful perioperative adjunct.

Understanding Dupuytren’s Contracture: More Than a Tight Cord

Dupuytren’s contracture is a benign but relentlessly progressive fibromatosis of the palmar and digital fascia. It predominantly affects the ring and little fingers, occurring as nodules, cords, and ultimately fixed flexion deformities that prevent full finger extension (Guimberteau & Panconi, 2013, as cited in Aakash et al., 2024). Globally, prevalence varies considerably by ethnicity, it is most common in men of Northern European descent over the age of 50, yet it remains underdiagnosed in its early, most therapeutically accessible stages (Aakash et al., 2024).

The Cellular Biology: Fibroblasts Gone Rogue

At its core, Dupuytren’s is a disease of disordered myofibroblast activity. Under normal conditions, palmar fibroblasts are quiescent connective tissue architects. In Dupuytren’s, a complex interplay of mechanical stress, ischaemia, genetic predisposition, and cytokine dysregulation triggers fibroblast proliferation and transdifferentiation into myofibroblasts, contractile, alpha-smooth-muscle-actin (α-SMA)-positive cells that both contract the surrounding matrix and hypersecrete extracellular matrix proteins (Townley et al., 2006).

The pivotal cytokine orchestrating this transformation is transforming growth factor-beta 1 (TGF-β1). TGF-β1 stimulates α-SMA expression, drives collagen type III overproduction, and suppresses matrix metalloproteinases (MMPs), the enzymes responsible for physiological collagen degradation (Verjee et al., 2009). The result is progressive extracellular matrix stiffening. Additional mediators including connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), interleukin-1, and epidermal growth factor amplify the fibrotic cascade (Aakash et al., 2024).

What This Means For You

Dupuytren’s is a condition where the tissue just beneath the skin of your palm gradually hardens and tightenss, caused by specific cells called myofibroblasts that, in effect, go into overdrive and start producing too much scar-like tissue. A chemical messenger called TGF-β1 acts like a faulty “on switch” that keeps those cells activated long after they should have settled down. The end result is a cord of thickened tissue that slowly pulls your finger(s) into a bent position you can’t straighten. Crucially, this is a biological process, not just mechanical tightness, which is exactly why treatments that work at the cellular level, like shockwave and laser therapy, can make a real difference, especially when caught early.

Disease Staging: Matching Biology to Clinical Presentation

Two classification systems guide clinical decision-making. Luck’s histological staging describes the underlying tissue biology, while Tubiana’s clinical staging quantifies the functional deficit. Together they inform not only prognosis but the selection and timing of intervention.

Luck’s Histological Stages

The proliferative stage is characterised by dense, metabolically active myofibroblast nodules with abundant type III collagen and a rich vascular supply.

The involutional stage sees myofibroblasts aligning along lines of mechanical tension, continuing to deposit type III collagen, with cords becoming palpable.

In the residual stage, myofibroblast density decreases as the tissue matures into hypocellular, type I collagen-dominant cords, mechanically rigid and functionally restrictive (Townley et al., 2006).

Tubiana’s Clinical Staging

Stage	Extension Deficit	Clinical Features	Intervention Window
N	0°	Palmar nodule(s), pitting, skin changes; no contracture	Ideal: ESWT + HPLT to slow progression
I	0–45°	Mild cord formation; minimal functional limitation	Conservative modalities; monitor closely
II	45–90°	Moderate deformity; functional grip impaired	Consider combined modalities; surgical discussion begins
III	90–135°	Severe contracture; activities of daily living significantly impaired	Pre-surgical optimisation; surgery likely indicated
IV	>135°	Very severe; PIP joint involvement common	Surgical priority; post-surgical ESWT + HPLT for recovery

What This Means For You

Think of staging as a map that tells us where you are in the journey of the disease, and crucially, how much room we still have to work with before surgery becomes the only option. If you’ve noticed a firm lump in your palm but your finger still straightens fully, you are at the earliest and most treatable stage. That’s genuinely good news. The further along the scale, the more the tissue has “set”, like wet cement that has hardened, and the harder it is to influence without a procedure. But even at more advanced stages, shockwave and laser therapy have a valuable role in preparing your hand for surgery and helping it recover faster afterwards.

EMS DolorClast® Shockwave Therapy: Physiology of the Acoustic Pulse

Extracorporeal shockwave therapy delivers high-energy acoustic pressure waves, characterised by rapid positive pressure peaks followed by tensile (negative) phases, into biological tissues. The EMS DolorClast® system offers both radial pressure wave (rESWT) and focused shockwave delivery, enabling clinicians to select the appropriate wave type based on the depth and nature of the target tissue. In Dupuytren’s, the superficial palmar fascia is typically accessible to radial application, while deeper cord and nodular tissue may benefit from focused delivery.

Mechanotransduction: Teaching Cells to Behave Differently

The primary mechanism of ESWT is mechanotransduction, the conversion of mechanical pressure stimuli into intracellular biochemical signals. Acoustic waves induce cell membrane deformation, activating mechanosensitive ion channels and integrin-linked kinase pathways. In fibrotic tissue, this mechanical signal downregulates pro-fibrotic gene expression and nudges myofibroblasts toward a less contractile phenotype (Notarnicola & Moretti, 2012; van der Jagt et al., 2013, as cited in Geyer et al., 2024).

Key Mechanism — TGF-β1 Suppression

Multiple in vitro and in vivo studies demonstrate that ESWT significantly reduces TGF-β1 expression in fibrotic tissue, directly suppressing the principal driver of myofibroblast differentiation. Downstream effects include reduced α-SMA expression, decreased fibronectin deposition, reduced type I collagen synthesis, and downregulation of the pro-fibrotic transcription factor Twist-1 (Wang et al., 2018).

Cavitation and Secondary Biological Signalling

The tensile (negative pressure) phase of the shockwave generates cavitation, the rapid formation and collapse of microscopic gas bubbles within the interstitial fluid. Bubble collapse produces localised microstreaming and shear forces that further stimulate cellular mechanoreceptors. Cavitation has been shown to activate mast cell degranulation and macrophage polarisation, releasing growth factors including vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and hypoxia-inducible factor-1α (HIF-1α), all of which promote neovascularisation and tissue remodelling (Mittermayr et al., 2012; as cited in Geyer et al., 2024).

Anti-Fibrotic Signalling Pathway Effects

A 2024 systematic review mapping shockwave-induced signalling pathways in fibrotic tissue identified consistent modulation of the TGF-β/Smad pathway, the Wnt/β-catenin axis, and NF-κB-driven inflammatory cascades (Geyer et al., 2024). This multi-pathway suppression of fibrosis is particularly relevant to Dupuytren’s, where the disease is sustained by overlapping pro-fibrotic signals rather than a single molecular defect.

ESWT also promotes macrophage phenotype switching from the pro-inflammatory M1 phenotype to the tissue-remodelling M2 phenotype. M2 macrophages secrete anti-inflammatory cytokines (IL-10, IL-4) and MMP-rich secretomes that facilitate controlled extracellular matrix degradation, precisely the biological environment needed to soften Dupuytren’s cords and permit finger extension (Geyer et al., 2024).

Clinical Evidence in Dupuytren’s Disease

The landmark DupuyShock randomised controlled trial (Knobloch et al., 2022) enrolled 52 patients with painful nodular Dupuytren’s disease in a prospective, blinded, placebo-controlled design. Patients received three sessions of focused electromagnetic high-energy ESWT (2,000 impulses, 3 Hz, 0.35 mJ/mm²) or matched placebo at weekly intervals. Active ESWT produced a statistically and clinically significant reduction in pain on the Visual Analogue Scale (VAS) that was sustained across the 18-month follow-up period, with no significant adverse events. Secondary outcomes including patient-reported DASH and URAM scores also favoured the active treatment group.

A 2024 systematic review in the Archives of Physical Medicine and Rehabilitation examined 26 studies (six meeting inclusion criteria, representing 145 cases) and concluded that ESWT produced meaningful improvements in pain, nodule consistency, and functional hand scores in Dupuytren’s, while noting that further high-quality trials are warranted to standardise dosing parameters (Sconfienza et al., 2024).

A prospective case series (Ersen et al., 2020) employing radial ESWT further documented reductions in palmar cord thickness on ultrasound and improvements in passive finger extension at 12-week follow-up, providing early imaging-level evidence of structural change in response to treatment.

What This Means For You

Shockwave therapy is not simply a device that shakes your hand, it sends precise sound-energy pulses deep into the problem tissue, and those pulses change the way your cells behave. The treatment essentially sends a message to the overactive scar-producing cells telling them to calm down and stop tightening. At the same time it switches your immune cells from “inflammation mode” into “repair and remodel mode,” and stimulates the growth of new blood vessels so the tissue gets better nourishment. In the research, a course of just three weekly shockwave sessions was enough to significantly reduce palm pain for up to 18 months, a meaningful result for a progressive condition with very few other non-surgical options. Treatments are typically well-tolerated, with most patients describing a firm pressure sensation during the session.

High-Power Laser Therapy: Light as a Biological Signal

High-power laser therapy (HPLT), also termed photobiomodulation therapy (PBMT) at higher power densities, delivers coherent, monochromatic light (typically in the near-infrared spectrum, 800–1,064 nm) at power outputs ranging from 5 to 25+ watts. At these intensities, HPLT penetrates deeply into palmar and digital soft tissues, reaching fascial layers that lower-power devices cannot access. The defining feature of HPLT over low-level laser therapy (LLLT) is not simply power, it is the ability to deliver therapeutically relevant fluences (energy doses per unit area, measured in J/cm²) at depth within an acceptable treatment time, while simultaneously producing a mild thermal effect that amplifies certain biological responses.

Primary Mechanism: Mitochondrial Photon Absorption

The foundational mechanism of photobiomodulation is the absorption of photons by mitochondrial chromophores, principally cytochrome c oxidase (Complex IV) of the electron transport chain. Photon absorption dissociates inhibitory nitric oxide from cytochrome c oxidase, restoring mitochondrial respiration, increasing ATP synthesis, and reducing the production of reactive oxygen species (ROS) (Hamblin, 2017). This mitochondrial energy boost has downstream effects on virtually every cellular process: proliferation, migration, collagen synthesis, cytokine secretion, and apoptosis.

Key Mechanism - Macrophage Polarisation & TGF-β Modulation

HPLT drives the M1-to-M2 macrophage transition, reducing pro-inflammatory TNF-α and IL-1β while upregulating anti-inflammatory IL-10. Critically for Dupuytren’s, photobiomodulation inhibits TGF-β1-induced fibroblast-to-myofibroblast transdifferentiation, the exact molecular step that initiates and sustains the disease (Moura Campos Pardini et al., 2024). This positions HPLT as a direct molecular antagonist to the central pathological driver of Dupuytren’s.

Effects on Fibroblast Biology and Collagen Remodelling

Photobiomodulation exerts nuanced, dose-dependent effects on fibroblast populations. At appropriately calibrated fluences, HPLT stimulates healthy fibroblast migration and controlled collagen synthesis, accelerating the transition through the proliferative and remodelling phases of tissue repair (Moura Campos Pardini et al., 2024). In the context of pathological fibrosis, the hallmark of Dupuytren’s, higher fluences or specific wavelength-protocol combinations have been shown to suppress fibroblast hyperproliferation, reduce collagen type I overproduction, and attenuate pro-fibrotic growth factor expression (Izzo et al., 2025).

A 2025 review synthesising omics data from laser-treated fibroblasts confirmed that HPLT modulates gene expression networks governing extracellular matrix synthesis, cell cycle progression, and inflammatory signalling, demonstrating that the effects of photobiomodulation are not simply thermal but represent a coherent, reproducible reprogramming of fibroblast phenotype (Izzo et al., 2025).

Anti-Inflammatory and Analgesic Effects

Nitric oxide released from mitochondria following photon absorption acts as a local vasodilator and anti-inflammatory mediator, increasing microvascular perfusion to hypoxic palmar tissue. The ischaemic microenvironment of early Dupuytren’s nodules, widely proposed as a co-driver of myofibroblast activation, is thereby attenuated. Simultaneously, HPLT reduces substance P concentrations in perilesional tissue, desensitising peripheral nociceptors and alleviating the nodular pain that significantly impairs hand function in early disease (Hamblin, 2017).

Specific Evidence: Laser Therapy in Dupuytren’s Disease

A prospective randomised clinical trial by Orhan et al. (2017) compared three active treatment arms in Dupuytren’s disease: ESWT, temperature-controlled high-energy adjustable multi-mode emission laser (THEAL, a high-power laser system), and stretching. Both ESWT and HPLT produced significantly greater improvements in pain, grip strength, and patient-reported hand function than stretching alone at 12-week follow-up, with comparable effect sizes between the two active modalities. The authors concluded that both therapies represent clinically meaningful conservative options in Dupuytren’s management. The complementary biological mechanisms of ESWT and HPLT suggest a strong rationale for combining them, targeting the fibrotic process through both mechanical (acoustic) and photonic pathways simultaneously.

Blue-light photobiomodulation studies on Dupuytren-derived fibroblasts have further shown direct suppression of fibroblast proliferation, migration speed, and reactive oxygen species generation (Mamalis et al., 2019), corroborating the anti-fibrotic cellular effects observed with near-infrared HPLT and broadening the mechanistic evidence base.

What This Means For You

High-power laser therapy uses a concentrated beam of near-infrared light, invisible to the naked eye, to penetrate through your skin and into the deeper palm tissue where the problem originates. Unlike a laser pointer or the low-powered devices you might find in some clinics, a high-power therapeutic laser reaches the layers we actually need to treat. At that depth, the light is absorbed by the energy-producing parts of your cells (the mitochondria), essentially recharging them so they can do their jobs better. The downstream effects include reduced inflammation, reduced pain, improved blood flow, and, critically for Dupuytren’s, a direct slowing of the process that turns ordinary tissue cells into the contractile, scar-producing cells driving your condition. In clinical trials comparing laser therapy head-to-head with shockwave therapy, both produced significantly better outcomes than stretching alone for Dupuytren’s pain and hand function, which is why we often use them together.

What Can These Modalities Do at Each Stage of Disease?

The therapeutic opportunities offered by ESWT and HPLT are not uniform across disease stages. Understanding what each modality can and cannot achieve at each histological and clinical stage is essential for setting realistic expectations with patients and for designing effective treatment protocols.

Nodular Stage (Luck Proliferative / Tubiana N–I): The Prime Intervention Window

The early nodular stage represents the most biologically accessible and therapeutically rewarding phase for both modalities. Myofibroblasts are metabolically active, the extracellular matrix is not yet irreversibly cross-linked, and the vasculature, though abnormal, remains present and responsive to growth factor stimulation.

At this stage, ESWT directly targets the nodular myofibroblast population via mechanotransduction, suppressing TGF-β1 and α-SMA expression to reduce the contractile potential of the lesion (Knobloch et al., 2022). The DupuyShock trial, conducted specifically in the nodular stage, demonstrated that pain, which can be a significant driver of functional avoidance and secondary deconditioning, responds robustly to focused ESWT, with effects maintained at 18 months. This pain reduction is likely mediated by substance P depletion and the normalisation of neurogenic inflammation within the nodule.

HPLT at this stage acts as a biological gatekeeper, inhibiting the TGF-β1-driven recruitment of additional fibroblasts into the myofibroblastic phenotype (Moura Campos Pardini et al., 2024). By driving M1→M2 macrophage polarisation, HPLT shifts the peri-nodular immune environment from one that sustains fibrosis to one that promotes regulated tissue remodelling. The cumulative effect of sequential or combined ESWT and HPLT treatments in the proliferative stage may slow, and in some cases stabilise, disease progression, preserving hand function and delaying or preventing the need for surgery.

Clinical Note

Clinical Pearl: The proliferative nodular stage is the window of greatest therapeutic leverage. Patients with palpable palmar nodules but minimal or no contracture (Tubiana N or I) are the ideal candidates for a proactive ESWT and HPLT programme aimed at slowing progression rather than merely managing symptoms.

What This Means For You

If you have a lump in your palm but your finger can still lie flat, you are at the best possible stage to act. At this point, the cells driving the problem are still active and ‘listening’, they can be influenced by shockwave and laser therapy. Think of it like weeds in a garden: they are far easier to deal with when they are young and shallow-rooted than once they have established a deep hold. A course of treatment now has a genuine chance of slowing or stabilising the disease, reducing the discomfort of the nodule, and buying meaningful time, potentially years, before you need to consider anything more invasive.

Involutional / Early Cord Stage (Luck Involutional / Tubiana I–II): Softening the Matrix

As the disease transitions into the involutional stage, palpable cords develop and passive finger extension begins to diminish. The myofibroblast network is now well-established, and collagen type III deposition is substantial. The biological challenge intensifies but remains meaningful for conservative intervention.

ESWT at higher energy flux densities (EFDs) can influence cord stiffness through two complementary mechanisms. First, repeated acoustic microtrauma to the cord tissue disrupts intermolecular collagen cross-links, producing localised collagen fibre disruption and matrix softening that can partially restore tissue extensibility (van der Jagt et al., 2013). Second, continued suppression of TGF-β1 and upregulation of MMPs via M2 macrophage activity promotes controlled enzymatic degradation of the excess type III collagen scaffold (Geyer et al., 2024).

HPLT in this stage contributes meaningfully by maintaining the anti-fibrotic, pro-remodelling microenvironment. Improved microvascular perfusion driven by VEGF and NO upregulation ensures that metabolic substrates for repair reach the cord tissue. The thermal component of HPLT, carefully calibrated to remain sub-ablative, increases tissue extensibility and reduces the viscosity of the pericordal connective tissue, facilitating stretching and manual therapy as adjuncts to treatment.

In the involutional stage, the combined goals of ESWT and HPLT shift from disease prevention toward cord softening, symptom control, and extension of the conservative management window before surgical intervention becomes unavoidable.

What This Means For You

If you can feel a cord forming and you are starting to notice your finger doesn’t quite lie flat anymore, you are at a stage where these treatments shift their focus slightly, rather than purely stopping progression, they are now also working to soften the cord itself and slow the rate at which your finger loses extension. Think of it like working on a stiff leather strap: shockwave and laser therapy help loosen the fibres, improve the suppleness of the tissue, and increase blood flow to an area that is becoming increasingly poorly nourished. You may not regain full extension through conservative treatment at this point, but you can meaningfully slow the decline, reduce pain, and maintain function for longer before a procedure is required.

Residual / Advanced Cord Stage (Luck Residual / Tubiana III–IV): Tissue Preparation and Adjunct Role

In advanced disease, the palmar cords are dominated by cross-linked type I collagen, and myofibroblast density is reduced. Direct anti-fibrotic effects of ESWT and HPLT on the cord itself become less biologically impactful because the primary pathological drivers, active myofibroblasts and nascent collagen synthesis, have largely subsided. The matrix is essentially “locked” by mature collagen cross-links.

However, these modalities retain significant value in advanced disease as perioperative tools, addressed in detail in the following section. They can also be used to address the soft tissue and neurovascular health of the surrounding hand, maintaining circulation, controlling inflammation, and preserving what functional tissue remains ahead of surgical correction.

What This Means For You

At this more advanced stage, the cord in your palm has largely “set” and is unlikely to be significantly reversed by conservative treatment alone, surgery is likely on the horizon. But that doesn’t mean shockwave and laser therapy have nothing to offer. They can keep the surrounding tissue as healthy and well-nourished as possible ahead of an operation, and they become a very important part of the recovery process afterwards. Many patients at this stage are surprised to learn that what happens in the weeks before and after their surgery can have as much impact on their long-term outcome as the operation itself.

When Is the Best Time to Administer These Modalities?

Timing is a biological variable, not merely a scheduling question. Both ESWT and HPLT exert their effects through tissue responses that require adequate recovery intervals between sessions and sufficient cumulative stimulus to drive lasting change.

Optimal Treatment Frequency and Intervals

Clinical protocols for ESWT in soft tissue fibrosis typically involve three to six sessions delivered at weekly intervals. Weekly spacing allows the initial inflammatory and mechanotransductive cascade from each session to resolve before the next is applied, permitting cumulative biological signalling without tissue irritation (Geyer et al., 2024). In the DupuyShock protocol, three weekly sessions of focused ESWT were sufficient to produce sustained 18-month benefit, suggesting that relatively short courses can anchor durable biological change in well-timed interventions (Knobloch et al., 2022).

HPLT sessions can be delivered more frequently, typically two to three times per week, given the absence of significant acoustic mechanical trauma. As photobiomodulation effects accumulate dose-dependently, more frequent initial sessions followed by a maintenance frequency may be most appropriate, particularly in active inflammatory or post-procedural contexts.

Act Early: The Disease Biology Argument

From a disease biology perspective, the strongest argument is to intervene early. The proliferative nodular stage features active, responsive cells with modifiable gene expression. Both ESWT and HPLT exert their greatest disease-modifying effects when TGF-β1-driven transdifferentiation is still occurring and the extracellular matrix remains amenable to remodelling. Waiting until Tubiana stage III before commencing conservative therapy misses the biological window most likely to alter disease trajectory.

Patients should ideally be directed toward ESWT and HPLT at first clinical detection of a palmar nodule, particularly if there is a known family history, occupational risk factors (vibrating tool use), or systemic associations (diabetes, epilepsy, alcohol dependency) that predict more aggressive disease progression.

What This Means For You

Timing your treatment isn’t complicated, the simple rule is: the sooner, the better. If you have Dupuytren’s and haven’t yet started any treatment, now is the right time regardless of where you are in the disease. For shockwave therapy, you’re typically looking at three to six sessions spaced a week apart, not an enormous time commitment for potentially years of benefit. Laser sessions can be done more frequently and fit comfortably around a working week. If you have a family history of Dupuytren’s, a job involving heavy vibration, or conditions like diabetes, these are all reasons to be proactive rather than wait-and-see.

Perioperative Applications: Priming for Surgery and Accelerating Recovery

For patients in whom conservative management has been maximised and surgical intervention, fasciotomy, fasciectomy, or collagenase injection, becomes necessary, ESWT and HPLT transition into a perioperative role. The biological rationale is compelling: neither modality is simply a passive pain reliever. Both actively modify the tissue environment in ways that directly influence surgical outcomes.

Pre-Surgical: Tissue Optimisation and Prehabilitation

The condition of the palmar soft tissue at the time of surgery is a meaningful predictor of post-operative outcome. Chronically fibrotic, hypovascular tissue heals more slowly, is more prone to wound dehiscence and post-surgical stiffness, and carries a higher recurrence risk following fasciotomy.

Pre-surgical ESWT, delivered in the four to eight weeks prior to the procedure, upregulates VEGF, eNOS, and HIF-1α in the target tissue, stimulating neovascularisation and significantly improving local blood flow (Ko et al., 2024). This vascular priming ensures that the tissue entering the operating theatre is better perfused, more metabolically competent, and more capable of supporting post-operative healing. Simultaneously, ESWT’s downregulation of TGF-β1 and α-SMA reduces the baseline pro-fibrotic state of the remaining tissue, potentially lowering the molecular substrate available to drive recurrence post-surgery.

Pre-surgical HPLT similarly contributes through macrophage polarisation, anti-inflammatory cytokine release, and mitochondrial activation of fibroblasts and keratinocytes in the palmar dermis. Well-perfused, mitochondrially energised skin and subcutaneous tissue tolerates surgical dissection better and re-epithelialises more effectively (Hamblin, 2017). For patients undergoing open fasciectomy, where wound complications and scar formation are meaningful post-operative concerns, this pre-conditioning of the dermal environment is clinically valuable.

Prehabilitation Recommendation: A course of three to four ESWT sessions plus six to eight HPLT sessions in the four weeks prior to surgical intervention is a rational biological strategy to optimise tissue vascularity, reduce pro-fibrotic signalling, and maximise healing capacity at the point of surgery.

What This Means For You

If your surgeon has told you that surgery is on the cards, starting shockwave and laser therapy before your operation date is one of the most effective things you can do for yourself right now. It is essentially like getting your hand “match fit” before the procedure, improving blood supply to the tissue, reducing the inflammatory load, and putting your cells in a much better position to heal quickly and cleanly after the surgery. We typically recommend beginning this in the four weeks prior to your procedure. It is worth having a conversation with both your surgeon and your clinician at Movement Mechanics to coordinate the best timing for your individual situation.

Post-Surgical: Accelerating Recovery and Reducing Recurrence Risk

Post-surgical Dupuytren’s tissue faces a paradox: the contracture has been surgically addressed, but the underlying biological predisposition to fibrosis remains. Post-operative scar formation and disease recurrence, with three-year recurrence rates of 31–45% following collagenase injection and needle fasciotomy respectively, represent the principal limitations of surgical management (Aakash et al., 2024).

ESWT in the post-surgical phase, initiated once wound healing is complete, typically four to six weeks post-procedure, targets the nascent scar and remodelling tissue with precisely the biological signals needed to prevent pathological fibrosis. Downregulation of α-SMA, TGF-β1, collagen type I, fibronectin, and Twist-1 in the post-surgical scar has been documented in ESWT-treated tissues, producing improvements in scar pliability, vascularity, height, and pigmentation (Wang et al., 2018). A 2024 study on deep dermal and subdermal fibrosis treated with focused and radial ESWT demonstrated satisfactory clinical improvement in pathological fibrosis with functional restoration across a cohort of 52 patients (Ko et al., 2024).

Post-surgical HPLT accelerates wound healing through its well-documented effects on epithelial cell proliferation, fibroblast migration, and neovascularisation (Izzo et al., 2025; Hamblin, 2017). A 2025 systematic review of photobiomodulation in post-surgical wound healing confirmed significant improvements in wound closure, pain reduction, and oedema across oral and maxillofacial surgical contexts, with mechanistic findings directly applicable to palmar tissue healing (Bayer et al., 2025). Initiation of HPLT at the wound margins in the early post-operative weeks, once wound integrity is confirmed, drives a more favourable cytokine milieu, nudging the healing tissue away from hypertrophic scar formation and toward functional, pliable connective tissue.

Critically, post-operative HPLT and ESWT are not simply wound care tools. By continuing to modulate the systemic fibroproliferative tendency of Dupuytren’s tissue, suppressing TGF-β1, polarising macrophages toward M2, and maintaining MMP activity, they represent a biologically coherent strategy for reducing the likelihood of disease recurrence in the surgical field.

What This Means For You

Surgery for Dupuytren’s has good success rates, but recurrence is a real and common issue, up to nearly half of patients see the disease return within three years after some procedures. This is because surgery addresses the mechanical problem (the cord pulling your finger down) but not the underlying biological tendency of your tissue to keep producing abnormal scar. Shockwave and laser therapy in the weeks after your operation, once your wound has healed, work to interrupt that recurring biological cycle. They help your scar heal softer and more pliably, encourage healthy new blood vessel growth, and continue to suppress the cellular signals that led to the contracture in the first place. Think of post-surgical treatment not as optional extra care, but as actively protecting the result your surgeon worked hard to achieve.

Conclusion: A Biologically Grounded Conservative Strategy

Dupuytren’s contracture is not, and has never been, purely a surgical problem. It is a biological problem, driven by TGF-β1, myofibroblast contractility, and disordered extracellular matrix remodelling, that eventually produces a mechanical consequence requiring surgical correction. EMS DolorClast® shockwave therapy and high-power laser therapy address the disease at the level of its biology: suppressing the molecular drivers of fibrosis, softening the tissue environment, stimulating vascularisation, and modulating the immune landscape from pro-fibrotic to pro-remodelling.

The clinical evidence, while still maturing, is directionally consistent. The DupuyShock RCT demonstrates that focused ESWT produces durable pain relief and functional benefit in the nodular stage. Prospective randomised comparisons confirm that high-power laser therapy matches ESWT in effect size for pain and function in early Dupuytren’s. Systematic reviews on both modalities in fibrotic conditions provide a robust mechanistic and clinical framework. No treatment reverses advanced cords without procedural intervention — but ESWT and HPLT meaningfully expand the biological window of conservative management, optimise tissue for surgery when it is needed, and reduce the molecular substrate for recurrence post-operatively.

At Movement Mechanics, we integrate EMS DolorClast® shockwave therapy and high-power laser therapy into a holistic, evidence-informed approach to Dupuytren’s contracture, one that begins at first nodule detection and continues as a perioperative partner when surgery is required. If you have been diagnosed with Dupuytren’s disease, or have noticed a nodule or tightness in your palm, we encourage you to seek assessment early, while the biological window for the greatest therapeutic impact remains open.

Clinical Disclaimer

This article is intended for educational purposes for patients and healthcare professionals. It does not constitute individual medical advice. Treatment decisions for Dupuytren’s contracture should be made in consultation with a qualified clinician following thorough clinical assessment. The modalities discussed are applied at Movement Mechanics within a broader clinical management framework.

---

Jonathan Hall M.Ost, BAppSci (Human Biology), PGCertHSc (Acupuncture), GradDipHeal, FIFA Diploma in Football Medicine

Jonathan Hall is the founder and principal Osteopath at Movement Mechanics Osteopathy. Jonathan specialises in Shockwave Therapy and Western Medical Acupuncture and is a Key Opinion Leader for EMS Swiss DolorClast. A fully qualified Osteopath registered with OCNZ, PNZ, PAANZ and ACC, Jonathan also founded Auckland Shockwave Therapy to bring evidence-based shockwave treatment to New Zealand using the industry-leading EMS DolorClast® device.

Book an appointment with Jonathan here.

Contact Us: hello@movementmechanics.nz

References

Aakash, P., Leung, C., & Bhatt, R. (2024). Dupuytren’s contracture: A review of the literature. PubMed Central, PMC11693408. https://pmc.ncbi.nlm.nih.gov/articles/PMC11693408/

Bayer, A., Karbowniczek, J., Karbowniczek, K., & Zyluk, A. (2025). Laser-based photobiomodulation in postoperative tissue healing in oral and maxillofacial surgery: Systematic review of RCTs. Journal of Clinical Medicine, 15(2), 613. https://doi.org/10.3390/jcm15020613

Ersen, O., Bostan, B., Ozdemir, M., & Sen, C. (2020). Radial extracorporeal shock wave therapy: A novel approach for the treatment of Dupuytren’s contractures. Medicine, 99(26), e21001. https://pmc.ncbi.nlm.nih.gov/articles/PMC7302658/

Geyer, M., Schuhmacher, A., Glowalla, C., Merk, H., & von Glinski, A. (2024). Systematic review on working mechanisms of signaling pathways in fibrosis during shockwave therapy. International Journal of Molecular Sciences, 25(21), 11729. https://doi.org/10.3390/ijms252111729

Hamblin, M. R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337–361. https://doi.org/10.3934/biophy.2017.3.337

Izzo, D., Ricca, I., Valguarnera, A., Amata, S., De Benedictis, G., La Rocca, R., Matarrese, M., & Abate, A. (2025). Photobiomodulation in fibroblasts: From light to healing through molecular pathways, omics and artificial intelligence. Frontiers in Bioengineering and Biotechnology, 13, 1675619. https://pmc.ncbi.nlm.nih.gov/articles/PMC12571845/

Knobloch, K., Hellweg, S., Sorg, H., & Nedelka, T. (2022). Focused electromagnetic high-energetic extracorporeal shockwave (ESWT) reduces pain levels in the nodular state of Dupuytren’s disease — a randomized controlled trial (DupuyShock). Lasers in Medical Science, 37, 323–333. https://doi.org/10.1007/s10103-021-03254-9

Ko, H., Lim, D., & Hong, J. (2024). Clinical efficacy and safety of low-energy extracorporeal shock wave therapy for various conditions of deep dermal and subdermal fibrosis. Skin Research and Technology, 30(9), e70082. https://doi.org/10.1111/srt.70082

Mamalis, A., Koo, E., Garcha, M., Murphy, W. J., Isseroff, R. R., & Jagdeo, J. (2019). Blue light irradiation and its beneficial effect on Dupuytren’s fibroblasts. Fibrogenesis & Tissue Repair, 12(1), 1. https://pmc.ncbi.nlm.nih.gov/articles/PMC6329497/

Moura Campos Pardini, P., Fonseca, S. A., de Sousa, A. N., & Renno, A. C. M. (2024). Photobiomodulation therapy targeting fibroblast cell regeneration and survival in diabetic wounds. Frontiers in Photonics, 5, 1423280. https://doi.org/10.3389/fphot.2024.1423280

Orhan, C., Alp, A., Simsek, I., & Gunduz, O. H. (2017). Short-term effect of shockwave therapy, temperature controlled high energy adjustable multi-mode emission laser or stretching in Dupuytren’s disease: A prospective randomized clinical trial. Journal of Biological Regulators and Homeostatic Agents, 31(3), 775–784.

Sconfienza, L. M., Orlandi, D., Corazza, A., Silvestri, E., Sardanelli, F., Abate, M., Kujawa, J., Draghi, F., Grassi, W., & Aliprandi, A. (2024). The effects of shock wave therapy on the symptoms and function of individuals with Dupuytren disease: A systematic review. Archives of Physical Medicine and Rehabilitation, 105(12), 2438–2446. https://doi.org/10.1016/j.apmr.2024.08.017

Townley, W. A., Baker, R., Sheppard, N., & Grobbelaar, A. O. (2006). Dupuytren’s contracture unfolded. BMJ, 332(7538), 397–400. https://doi.org/10.1136/bmj.332.7538.397

Verjee, L. S., Midwood, K., Davidson, D., Essex, D., Sandison, A., & Nanchahal, J. (2009). Unravelling the signalling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. Journal of Cellular Physiology, 220(2), 312–322. https://doi.org/10.1002/jcp.21765

Wang, C. J., Ko, J. Y., Chou, W. Y., Huang, C. C., & Sun, Y. C. (2018). ESWT alters the expression of fibrosis-related molecules in fibroblast derived from human hypertrophic scar. Evidence-Based Complementary and Alternative Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC5796073/

Disclaimer: This content is for educational purposes and does not constitute medical advice. Individual patient suitability for perioperative shockwave and laser therapy should be assessed by a qualified healthcare practitioner in direct collaboration with the treating surgical team. Contraindications to ESWT and photobiomodulation must be screened for prior to treatment.